Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients

YILDIRIM E., ŞAHİN G., Kaltus Z., ÇOLAK E.

CLINICAL LABORATORY, cilt.65, sa.11, ss.2079-2089, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 65 Sayı: 11
  • Basım Tarihi: 2019
  • Doi Numarası: 10.7754/clin.lab.2019.190343
  • Dergi Adı: CLINICAL LABORATORY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2079-2089
  • Anahtar Kelimeler: tacrolimus, CYP3A5, ABCB1, polymorphism, pharmacokinetics, SINGLE-NUCLEOTIDE POLYMORPHISMS, TROUGH CONCENTRATION, DOSE REQUIREMENTS, DRUG-INTERACTIONS, EARLY-STAGE, PHARMACOKINETICS, CYTOCHROME-P450, CYCLOSPORINE, METABOLISM, MDR1
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Background: Tacrolimus (Tac) is a calcineurin inhibitor (CNI). Its therapeutic range is narrow and pharmacokinetic properties vary among patients. CYP3A5 and MDR1 single-nucleotide polymorphisms (SNPs) are the most effective polymorphisms that play an significant role in the pharmacokinetics of Tac.